At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 181 enrolled
Drug / intervention
Obinutuzumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating Obinutuzumab and Placebo for Graft vs. Host Disease. Completed, enrolled 181 participants across 5 sites.
Detailed Summary
This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft vs. Host Disease
CountriesUnited States
CollaboratorsRoche-Genentech
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartNov 2016
Primary CompletionNov 2023
Study CompletionNov 2024
TodayJul 2026
First PostedAug 15, 2016
Enrollment StartNov 29, 2016
Primary CompletionNov 29, 2023
Study CompletionNov 14, 2024
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 9.9 years ago
Interventions
Obinutuzumabdrug
B cell depletion
Placebodrug
Placebo